- JP-listed companies
- Income statement
(4586) Income statement
Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 741 | 88 | 69 | 26 | 38 | 22 | 198 | 8 | 170 | 115 | 8 | 59 | 30 | 258 | 128 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | 9 | 12 | 8 | 7 | 2 | 5 | 4 | 2 | 3 | 2 | 0 | 1 |
| Gross profit | - | - | - | 17 | 25 | 15 | 191 | 6 | 165 | 111 | 6 | 57 | 27 | 258 | 127 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 1,020 | 1,025 | 1,358 | 1,175 | 1,279 | 1,793 | 1,242 | 1,067 | 1,156 | 961 | 1,051 | 1,069 |
| Operating income | - | - | - | -1,003 | -1,000 | -1,343 | -983 | -1,273 | -1,628 | -1,130 | -1,061 | -1,099 | -934 | -793 | -942 |
| Income before tax | -480 | -578 | -617 | -1,012 | -991 | -1,301 | -989 | -1,285 | -1,633 | -1,153 | -1,074 | -1,112 | -931 | -755 | -937 |
| Pretax margin (%) | -64.7 | -658.7 | -899.2 | -3,850.5 | -2,634.7 | -5,824.7 | -498.9 | -15,303.6 | -961.5 | -1,001.4 | -12,865.5 | -1,869.8 | -3,151.1 | -292.8 | -731.9 |
| Provision for income taxes | - | - | - | 4 | 4 | 4 | 4 | 2 | 5 | 8 | 1 | 2 | 3 | 4 | 12 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | -433 | -571 | -622 | -1,017 | -878 | -1,259 | -884 | -1,268 | -1,616 | -1,115 | -1,060 | -1,111 | -933 | -807 | -937 |
| Earnings per share | -151.26 | -196.25 | -113.48 | -151.96 | -131.21 | -155.48 | -103.16 | -126.77 | -134.32 | -68.61 | -49.62 | -43.81 | -26.82 | -18.56 | -17.44 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |